HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Published online before print June 16, 2003

This Article Full Text Full Text (PDF) All Versions of this Article: jlb.0103041v1 74/2/151    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lund, R. D. Articles by Lawrence, J. M. Search for Related Content PubMed PubMed Citation Articles by Lund, R. D. Articles by Lawrence, J. M.

(Journal of Leukocyte Biology. 2003;74:151-160.)
© 2003 by Society for Leukocyte Biology

Retinal transplantation: progress and problems in clinical application

R. D. Lund^*, S. J. Ono, D. J. Keegan and J. M. Lawrence

^* Moran Eye Center, University of Utah, Salt Lake City; and
Department of Ocular Immunology and
Transplantation Unit, Institute of Ophthalmology, University College, London, United Kingdom

Correspondence: Professor R. D. Lund, Moran Eye Center, North Medical Drive, University of Utah Health Science Center, Salt Lake City, UT 84132. E-mail: raymond.lund{at}hsc.utah.edu

There is currently no real treatment for blinding disorders that stem from the degeneration of cells in the retina and affect at least 50 million individuals worldwide. The excitement that accompanied the first studies showing the potential of retinal cell transplantation to alleviate the progress of blindness in such diseases as retinitis pigmentosa and age-related macular degeneration has lost some of its momentum, as attempts to apply research to the clinic have failed so far to provide effective treatments. What these studies have shown, however, is not that the approach is flawed but rather that the steps that need to be taken to achieve a viable, clinical treatment are many. This review summarizes the course of retinal transplant studies and points to obstacles that still need to be overcome to improve graft survival and efficacy and to develop a protocol that is effective in a clinical setting. Emphasis is given particularly to the consequences of introducing transplants to sites that have been considered immunologically privileged and to the role of the major histocompatibility complex classes I and II molecules in graft survival and rejection.

Key Words: photoreceptor degeneration • grafting • immune rejection

This article has been cited by other articles:

				H. Xu, D. D. Sta. Iglesia, J. L. Kielczewski, D. F. Valenta, M. E. Pease, D. J. Zack, and H. A. Quigley Characteristics of Progenitor Cells Derived from Adult Ciliary Body in Mouse, Rat, and Human Eyes Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1674 - 1682. [Abstract] [Full Text] [PDF]

				P. J Francis Genetics of inherited retinal disease. J R Soc Med, April 1, 2006; 99(4): 189 - 191. [Full Text] [PDF]

				E. Banin, A. Obolensky, M. Idelson, I. Hemo, E. Reinhardtz, E. Pikarsky, T. Ben-Hur, and B. Reubinoff Retinal Incorporation and Differentiation of Neural Precursors Derived from Human Embryonic Stem Cells Stem Cells, February 1, 2006; 24(2): 246 - 257. [Abstract] [Full Text] [PDF]

				M. T. Pardue, M. J. Phillips, H. Yin, B. D. Sippy, S. Webb-Wood, A. Y. Chow, and S. L. Ball Neuroprotective Effect of Subretinal Implants in the RCS Rat Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 674 - 682. [Abstract] [Full Text] [PDF]